These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 3576675)
1. Systemic macrophage activation by liposomes containing MTP-PE in mice immunosuppressed with cyclosporine. LeGrue SJ; Saiki I; Romerdahl CA; Fidler IJ Transplantation; 1987 Apr; 43(4):584-6. PubMed ID: 3576675 [No Abstract] [Full Text] [Related]
2. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens. Ullrich SE; Fidler IJ J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559 [TBL] [Abstract][Full Text] [Related]
3. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Fidler IJ; Fan D; Ichinose Y Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. Talmadge JE; Schneider M; Collins M; Phillips H; Herberman RB; Wiltrout RH J Immunol; 1985 Aug; 135(2):1477-83. PubMed ID: 4008928 [TBL] [Abstract][Full Text] [Related]
5. Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties. Nayar R; Schroit AJ; Fidler IJ Methods Enzymol; 1986; 132():594-603. PubMed ID: 3547028 [No Abstract] [Full Text] [Related]
6. Lipopolysaccharide and liposome-encapsulated MTP-PE-induced cytotoxicity and release of eicosanoids, tumor necrosis factor- alpha and nitric oxide in liver macrophages. Dieter P; Ambs P; Fitzke E; Schwende H Adv Exp Med Biol; 1997; 407():485-90. PubMed ID: 9321995 [No Abstract] [Full Text] [Related]
7. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Saiki I; Milas L; Hunter N; Fidler IJ Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858 [TBL] [Abstract][Full Text] [Related]
8. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL). Phillips NC; Moras ML; Chedid L; Petit JF; Tenu JP; Lederer E; Bernard JM; Lefrancier P J Biol Response Mod; 1985 Oct; 4(5):464-74. PubMed ID: 3935756 [TBL] [Abstract][Full Text] [Related]
9. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. Fidler IJ; Fogler WE; Brownbill AF; Schumann G J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979 [TBL] [Abstract][Full Text] [Related]
10. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430 [TBL] [Abstract][Full Text] [Related]
11. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases. Schroit AJ; Fidler IJ Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445 [No Abstract] [Full Text] [Related]
12. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs. Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784 [TBL] [Abstract][Full Text] [Related]
13. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide. Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085 [TBL] [Abstract][Full Text] [Related]
14. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. Sone S; Mutsuura S; Ogawara M; Tsubura E J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409 [TBL] [Abstract][Full Text] [Related]
15. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252 [TBL] [Abstract][Full Text] [Related]
16. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Koff WC; Showalter SD; Hampar B; Fidler IJ Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772 [TBL] [Abstract][Full Text] [Related]
18. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Talmadge JE; Lenz BF; Klabansky R; Simon R; Riggs C; Guo S; Oldham RK; Fidler IJ Cancer Res; 1986 Mar; 46(3):1160-3. PubMed ID: 3943092 [TBL] [Abstract][Full Text] [Related]
19. Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide. Shaw JM; Futch WS; Schook LB Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6112-6. PubMed ID: 3413079 [TBL] [Abstract][Full Text] [Related]
20. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status. Frost H Biotherapy; 1992; 4(3):199-204. PubMed ID: 1599803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]